New drug trial aims to tame debilitating gut diseases
NCT ID NCT07216014
Summary
This study is testing how well and how safely a drug called an IL-23 monoclonal antibody works for people with moderate to severe Crohn's disease or ulcerative colitis. It will follow 200 adult patients for about a year, checking their symptoms, doing scans and scopes, and collecting samples. The main goal is to see if patients can achieve remission without needing steroid medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE AND ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.